SR 49059 is a selective, nonpeptide antagonist of the V subtype of the vasopressin receptor (K = 1.1-6.3 nM in human). It demonstrates ≥2 orders of magnitude lower affinity for V, V, and oxytocin receptors and does not exhibit any intrinsic agonist activity. SR 49059 can inhibit arginine vasopressin-induced human platelet aggregation with an IC value of 3.7 nM.
SR 49059 is a potent, orally active, selective vasopressin V1a antagonist with a Ki vaule of 1.4 nM.
IC50&Target
V1a Receptor
体内研究
SR 49059 (2 mg/kg and 30 mg/kg); Intraperitoneal injection; When injected early after occlusion of the middle cerebral artery (MCA), it showed neuroprotective effects against ischemic brain injury.
Animal Model:
Male Wistar rats, weighing 300 to 350 g, cerebral focal ischemia model
Dosage:
2 mg/kg and 30 mg/kg dissolved in 10% dimethyl sulfoxide
Administration:
Intraperitoneal injection, once
Result:
Significantly reduced infarction volume measured at 48 hours after the arterial occlusion. Reduced neurological deficits and ischemic brain edema.